drugset / Trial / NCT00285051
Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy
Phase 2
Terminated
6 enrolled
Rafa Laboratories
Teva Branded Pharmaceutical Products R&D, Inc. · collab
RandomizedCrossoverTriple-blindTreatment
Summary
Patients will be treated for 2 consecutive chemo cycles with the study drug for one and placebo for the other. In addition, patients will receive an injection before the chemo, either ondansetron (if receiving placebo inhalation) or normal saline) if receiving active study drug. They will take study medication for 3 days, 4 times daily and fill out VAS scores before and after doses. Patients will be given rescue medication with each dose.
Timeline
- Start
- 2005-11
- Primary completion
- 2009-02
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Delta-8-Tetrahydrocannabinol | Other / unclassified | 300 ug | Inhaled |
| Subject | Delta-8-Tetrahydrocannabinol | Other / unclassified | 600 ug | Inhaled |
| Subject | Ondansetron | Other / unclassified | — | Intravenous |